Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity.
Karnell JL, Albulescu M, Drabic S, Wang L, Moate R, Baca M, Oganesyan V, Gunsior M, Thisted T, Yan L, Li J, Xiong X, Eck SC, de Los Reyes M, Yusuf I, Streicher K, Müller-Ladner U, Howe D, Ettinger R, Herbst R, Drappa J. Karnell JL, et al. Among authors: albulescu m. Sci Transl Med. 2019 Apr 24;11(489):eaar6584. doi: 10.1126/scitranslmed.aar6584. Sci Transl Med. 2019. PMID: 31019027
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
Weinblatt ME, McInnes IB, Kremer JM, Miranda P, Vencovsky J, Guo X, White WI, Ryan PC, Godwood A, Albulescu M, Close D, Burmester GR. Weinblatt ME, et al. Among authors: albulescu m. Arthritis Rheumatol. 2018 Jan;70(1):49-59. doi: 10.1002/art.40323. Arthritis Rheumatol. 2018. PMID: 28941039 Free PMC article. Clinical Trial.
Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.
Burmester GR, McInnes IB, Kremer JM, Miranda P, Vencovský J, Godwood A, Albulescu M, Michaels MA, Guo X, Close D, Weinblatt M. Burmester GR, et al. Among authors: albulescu m. Arthritis Rheumatol. 2018 May;70(5):679-689. doi: 10.1002/art.40420. Epub 2018 Mar 31. Arthritis Rheumatol. 2018. PMID: 29361199 Free PMC article. Clinical Trial.
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.
Bruce IN, Furie RA, Morand EF, Manzi S, Tanaka Y, Kalunian KC, Merrill JT, Puzio P, Maho E, Kleoudis C, Albulescu M, Hultquist M, Tummala R. Bruce IN, et al. Among authors: albulescu m. Ann Rheum Dis. 2022 Jul;81(7):962-969. doi: 10.1136/annrheumdis-2021-221847. Epub 2022 May 17. Ann Rheum Dis. 2022. PMID: 35580976 Free PMC article. Clinical Trial.
A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale.
Khanna D, Denton CP, Assassi S, Kuwana M, Allanore Y, Domsic RT, Kleoudis C, Xu J, Csomor E, Seo C, Albulescu M, Tummala R, Al-Mossawi H, Kalyani RN, Del Galdo F. Khanna D, et al. Among authors: albulescu m. Clin Exp Rheumatol. 2024 Aug;42(8):1635-1644. doi: 10.55563/clinexprheumatol/s8qcyu. Epub 2024 Aug 14. Clin Exp Rheumatol. 2024. PMID: 39152751 Free article.